RBC cuts Jazz Pharmaceuticals price target to $296
Benzinga reports RBC Capital cut its Jazz Pharmaceuticals price target to $296 per share from $299.
Benzinga reports RBC Capital cut its Jazz Pharmaceuticals price target to $296 per share from $299.